PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Joseph Thome - Cowen Alexander Xenakis - Truist Raju Prasad - William Blair Gena Wa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-35969 PTC Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 Corporate Court South Plainfield, NJ 07080 (Address of principal executive offices) (Zip Code) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

PTC 2022 Corporate Presentation September 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to guidance relating to 2022 total revenue, 2022 DMD franchise net product revenue, 2022 operating expenditure guidance and future revenue guidance and s ...

PTC Therapeutics (NASDAQ:PTCT) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President, Head of Global Commercial & Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Eric Joseph - JPMorgan Raju Prasad - William Blair Kristen Kluska - Cantor Fitzgerald Joe Thome - Cowen & Company Tazeen Ahmad - Ban ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35969 PTC Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3416587 (State ...

Translarna™ (Ataluren) Study 041 Topline Results 21st June 2022 Forward looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the commercialization of its products and product candidates ...

PTC 2022 Corporate Presentation May 2022 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to guidance relating to 2022 total net product revenue, 2022 DMD franchise net product revenue, 2022 operating expenditure guidance and future revenue guidance a ...

Start Time: 16:30 January 1, 0000 5:36 PM ET PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2022 Earnings Conference Call May 03, 2022, 16:30 PM ET Company Participants Stuart Peltz - Founder and CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Kylie O’Keefe - SVP, Global Commercial and Corporate Strategy Conference Call Participants Eric Joseph - JPMorgan Rick Krause - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Joseph Thome - Cowen and Company Gena Wang - Barclays Robyn K ...

Financial Performance - Translarna generated $79.2 million in net sales during the quarter ended March 31, 2022[213]. - Emflaza achieved $48.6 million in net sales for the same quarter[213]. - For the three months ended March 31, 2022, net product sales outside of the United States were $81.2 million, compared to $47.8 million for the same period in 2021, representing a 70.0% increase[246]. - Net product sales in the United States for the same period were $48.6 million, up from $43.5 million in 2021, indicating an 11.8% growth[246]. - Net product revenue for the three months ended March 31, 2022, was $129.8 million, an increase of $38.6 million, or 42%, from $91.3 million for the same period in 2021[267]. - Translarna net product revenues were $79.2 million for the three months ended March 31, 2022, an increase of $32.7 million, or 70%, compared to $46.5 million for the same period in 2021[267]. - Emflaza net product revenues were $48.6 million for the three months ended March 31, 2022, an increase of $5.1 million, or 12%, compared to $43.5 million for the same period in 2021[267]. - Royalty revenue for the three months ended March 31, 2022, was $18.9 million, an increase of $12.2 million, or over 100%, from $6.7 million for the same period in 2021[269]. Research and Development - The company anticipates reporting results from the placebo-controlled trial of Study 041 by the end of Q2 2022[214]. - The company initiated a Phase 2 study of PTC518 for Huntington's disease in Q1 2022, expecting initial results by the end of 2022[222]. - A registration-directed Phase 3 trial for PTC923 for phenylketonuria was initiated in Q3 2021, with results expected by the end of 2022[227]. - The company completed a Phase 1 trial for PTC857, which was well-tolerated, and initiated a Phase 2 trial for amyotrophic lateral sclerosis in Q1 2022[226]. - The company expects to incur ongoing research and development expenses for its products and product candidates, including studies for emvododstat for COVID-19 and other therapeutic areas[238]. - Research and development expenses for the three months ended March 31, 2022, were $140.1 million, an increase of $5.6 million, or 4%, from $134.5 million for the same period in 2021[274]. Regulatory and Market Access - The marketing authorization for Translarna in the EEA is subject to annual review and renewal, with a renewal request submitted in February 2022[214]. - The company expects a regulatory decision on Waylivra for familial partial lipodystrophy in the second half of 2022[220]. - The company’s ability to generate revenue from Translarna is dependent on maintaining marketing authorizations and securing market access in various territories[283]. - The company plans to submit a BLA to the FDA for PTC-AADC in the third quarter of 2022[294]. Expenses and Financial Obligations - The company had an accumulated deficit of $2,224.7 million as of March 31, 2022, with a net loss of $126.7 million for the three months ended March 31, 2022[236]. - Selling, general and administrative expenses were $73.3 million for the three months ended March 31, 2022, an increase of $12.2 million, or 20%, from $61.1 million for the same period in 2021[275]. - Interest expense, net was $23.5 million for the three months ended March 31, 2022, an increase of $4.4 million, or 23%, from $19.2 million for the same period in 2021[277]. - The company expects selling, general and administrative expenses to increase in future periods due to ongoing commercialization efforts[261]. - The company anticipates significant expenses related to commercialization efforts in various regions, including the United States and EEA, and ongoing research and development costs[294]. - The company expects to pay $70.0 million to former equityholders of Agilis upon achieving certain milestones in 2022 related to PTC-AADC[306]. - The company may need to obtain substantial additional funding to sustain operations and achieve profitability[308]. Cash Flow and Financing - As of March 31, 2022, the company had cash, cash equivalents, and marketable securities totaling $587.8 million[290]. - Net cash used in operating activities was $97.4 million for the three months ended March 31, 2022, compared to $100.2 million for the same period in 2021[291]. - The company incurred net cash provided by investing activities of $49.0 million for the three months ended March 31, 2022, primarily due to net sales and redemption of marketable securities[292]. - The company closed a private offering of $150.0 million in aggregate principal amount of 3.00% convertible senior notes due 2022, receiving net proceeds of approximately $145.4 million after expenses[285]. - The company believes its cash flows from product sales and existing cash will be sufficient to fund operating expenses for at least the next twelve months[298]. Impact of COVID-19 - The COVID-19 pandemic has not significantly affected revenue generation, but may impact future revenue due to operational challenges[210]. Product Pipeline - The company has a pipeline of product candidates focused on multiple therapeutic areas, including rare diseases and oncology[230]. - The company may seek to expand its product pipeline through in-licensing or acquiring rights to new products, which could increase future capital requirements[239]. - The company expects to incur substantial costs in connection with regulatory submissions and commercialization efforts for its products[294].

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2021 Earnings Conference Call February 22, 2022 4:30 PM ET Company Participants Kylie O'Keefe - VP, Head of Global Strategic Marketing & Business Intelligence Stuart Peltz - Co-Founder & CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Conference Call Participants Alethia Young - Cantor Fitzgerald & Co. Joseph Thome - Cowen and Company Eric Joseph - JPMorgan Chase & Co. Raju Prasad - William Blair & Company Brian Abrahams - RBC Capital Ma ...